| 1 |
33447420 | Plasma thymidylate synthase and dihydrofolate reductase mRNA levels as potential predictive biomarkers of pemetrexed sensitivity in patients with advanced non-small cell lung cancer. | 2020 Dec |
7 |
| 2 |
26277606 | The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients. | 2016 Jan |
1 |
| 3 |
23709418 | Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. | 2013 Jul |
1 |
| 4 |
22975265 | Pemetrexed alters folate phenotype and inflammatory profile in EA.hy 926 cells grown under low-folate conditions. | 2012 Dec 5 |
2 |
| 5 |
23060591 | Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer. | 2012 Oct |
5 |
| 6 |
21367480 | Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. | 2011 Oct |
4 |
| 7 |
20020129 | Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. | 2010 Aug |
3 |
| 8 |
19221750 | Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. | 2009 Oct |
1 |
| 9 |
18633241 | [Pemetrexed]. | 2008 Jun |
1 |
| 10 |
19419926 | New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer. | 2008 |
2 |
| 11 |
17465208 | Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow. | 2007 Mar-Apr |
2 |
| 12 |
17534577 | In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. | 2007 Oct |
1 |
| 13 |
16352313 | Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets. | 2006 Jun 21 |
1 |
| 14 |
16472713 | Clinical experience with pemetrexed in breast cancer. | 2006 Feb |
2 |
| 15 |
16807459 | Clinical studies of pemetrexed and gemcitabine combinations. | 2006 May |
1 |
| 16 |
28140044 | Clinical Experience With Pemetrexed in Breast Cancer. | 2006 Feb |
2 |
| 17 |
15821248 | Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab. | 2005 Apr |
1 |
| 18 |
15339059 | Pemetrexed: its promise in treating non-small-cell lung cancer. | 2004 Jul |
2 |
| 19 |
15359285 | Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene. | 2004 Dec |
6 |
| 20 |
15655931 | Biochemical pharmacology of pemetrexed. | 2004 Nov |
2 |
| 21 |
15655932 | Overview of phase I/II pemetrexed studies. | 2004 Nov |
1 |
| 22 |
15655941 | Translational research with pemetrexed in breast cancer. | 2004 Nov |
4 |
| 23 |
12722017 | Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer. | 2003 Apr |
1 |
| 24 |
14596699 | The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. | 2003 Jul |
1 |
| 25 |
12023791 | Pemetrexed: a promising new treatment for breast cancer. | 2002 Apr |
1 |
| 26 |
12023793 | Pemetrexed in the treatment of selected solid tumors. | 2002 Apr |
1 |
| 27 |
12094334 | Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors). | 2002 Jun |
1 |
| 28 |
12094337 | Pemetrexed: translational research in breast cancer. | 2002 Jun |
1 |
| 29 |
12118332 | Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells. | 2002 Aug |
1 |
| 30 |
12209673 | The pemetrexed/gemcitabine combination in pancreatic cancer. | 2002 Aug 15 |
1 |
| 31 |
12571807 | Pemetrexed safety and dosing strategy. | 2002 Dec |
1 |
| 32 |
12571808 | Preclinical and clinical studies with combinations of pemetrexed and gemcitabine. | 2002 Dec |
1 |
| 33 |
12571813 | Pemetrexed: an active new agent for breast cancer. | 2002 Dec |
1 |
| 34 |
11252887 | Gemcitabine and Pemetrexed disodium in treating breast cancer. | 2001 Feb |
2 |
| 35 |
11384244 | Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines. | 2001 Jun 7 |
1 |
| 36 |
11742712 | Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. | 2001 Dec |
2 |
| 37 |
11763166 | Pemetrexed disodium (Eli Lilly). | 2001 Nov |
3 |
| 38 |
10598557 | Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines. | 1999 Apr |
1 |
| 39 |
10598560 | Overview of phase I trials of multitargeted antifolate (MTA, LY231514). | 1999 Apr |
1 |
| 40 |
10598563 | Overview of phase II trials of MTA in solid tumors. | 1999 Apr |
1 |
| 41 |
9717988 | Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. | 1998 |
2 |
| 42 |
9762351 | Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). | 1998 |
3 |
| 43 |
9067281 | LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. | 1997 Mar 15 |
3 |